Insmed Inc - Company Profile
Powered by 
All the data and insights you need on Insmed Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Insmed Inc Strategy Report
- Understand Insmed Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Insmed Inc (Insmed) is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium avium complex (MAC) lung infection and NTM lung infections caused by MAC in adult patients. The company uses its proprietary, liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib for non-cystic fibrosis (non-CF) bronchiectasis, cystic fibrosis and COVID-19; TPIP, an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company operates in the US, the UK, the Netherlands, Ireland, Germany, Italy, France and Japan through its subsidiaries. Insmed is headquartered in Bridgewater, New Jersey, the US.
Headquarters
United States of America
Address
700 Us Highway 202/206, Bridgewater, New Jersey, 08807
Website
insmed.com
Telephone
1 908 9779900
No of Employees
912
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INSM (NASD)
Revenue (2022)
$305.2M
24.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-55.7%
(2022 vs 2021)
Market Cap*
$3.9B
Net Profit Margin (2022)
XYZ
-25.1%
(2022 vs 2021)
* As of and is in US$
Insmed Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product: | ARIKAYCE |
| ARIKAYCE : Nontuberculous Mycobacteria Lung Disease | PULMOVANCE |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company collaborated with Google Cloud to transform the drug discovery, development, and commercialization landscape of the life sciences industry through the use of generative AI. |
| 2023 | Acquisitions/Mergers/Takeovers | In July, the company acquired Adrestia Therapeutics. |
| 2023 | New Products/Services | In May, the company introduced new research platforms and capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More". |
Competitor Comparison
| Key Parameters | Insmed Inc | Gilead Sciences Inc | Vertex Pharmaceuticals Inc | Alfresa Pharma Corp | Chiesi SA |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | France |
| City | Bridgewater | Foster City | Boston | Osaka | Courbevoie |
| State/Province | New Jersey | California | Massachusetts | Osaka | Centre |
| No. of Employees | 912 | 18,000 | 5,400 | 960 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Lewis | President; Chairman; Chief Executive Officer | Executive Board | 2018 | 54 |
| Sara M. Bonstein | Chief Financial Officer | Senior Management | 2020 | 42 |
| Roger Adsett | Chief Operating Officer | Senior Management | 2019 | 54 |
| Martina Flammer, M.D. | Chief Medical Officer | Senior Management | 2019 | 59 |
| Eugene Sullivan, M.D. | Chief Product Strategy Officer | Senior Management | 2017 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward